We can't find the internet
Attempting to reconnect
13385.1;4 PFFLR-LS
A novel antibody based therapy for allergy
Résumé
A novel antibody based therapy for allergy
Textes supplémentaires
Abstract
We intend to develop bispecific antibodies that target specifically IgE bearing B cells. Such bispecific antibodies will be evaluated for their capacity to inhibit IgE synthesis as well as to knock out IgE bearing B cells. The development of such antibodies represent an innovative approach as current therapeutic IgE-specific antibodies do not affect IgE production and therefore must be given frequently to maintain sufficient suppression of serum IgE. Glenmark has developed the necessary expression systems for bispecific antibodies and has all license agreement to market such antibodies. The academic partner has the individual anti-IgE antibodies that will be used for the construction of bispecific antibodies and will perform the preclinical testing in order to decide which construct will be taken up in the production pipeline.
Participants
Monique Vogel
Kontaktperson
monique.vogel@iib.unibe.ch
Inselspital Bern Monique Vogel Sahlihaus 2 3010 Bern BE CH
Détails du projet
- Office de recherche
- INNOSUISSE
- Statut du projet
- Abgeschlossen
- Type de projet
- Forschungsprojekt
- Date de début
- 2012-03-31
- Date de fin
- 2015-12-20
- Coûts totaux approuvés
- CHF 338216.00
- Section
- 5 KTI
- Domaine politique NABS
- Nicht aufteilbare / nicht zuteilbare Forschung
Disciplines de recherche
- T115 Medical technology 100.0%